CSA-NGAL score

Scientific Advisory Board

Cardiac surgery-associated acute kidney injury (CSA-AKI):

Discussion Cardiac surgery-associated NGAL (CSA-NGAL) score

BioPorto is proud to announce that the paper "The cardiac surgery-associated NGAL score: a potential tool to monitor acute tubular damage" authored by our esteemed Scientific Advisory Board chaired by Prof. Dr. med Jean-Louis Vincent have been accepted in The Journal of Thoracic and Cardiovascular Surgery.
 
 Download paper here.

BioPorto Scientific Advisory Board members are

  • Prof. Dr. med Jean-Louis Vincent, Erasme, Belgium. (Chair)
  • Assoc. Prof. Dr. med Andrew Lewington, St. James’s University Hospital, Leeds, UK. 
  • Director Dr. med Claudio Ronco, San Bortolo Hospital, Vicenza, Italy
  • Prof. Dr. med Laurent Jacob, Saint-Louis Hospital, Paris, France
  • Prof. Dr. med Michael Haase, Otto-von Guericke University, Magdeburg, Germany
  • Dr. med, PhD, Hilde RH de Geus, Eramus University Medical Center Rotterdam, NL

Important recognition of NGAL as a potential tool to monitor acute tubular damage

While a large number of scientific articles documenting NGAL’s use as a marker for the detection of acute kidney injury have been published, the Advisory Board’s white paper is the first article suggesting guidelines based on reported clinical use of NGAL for the intervention and patient management both before and after the operation based on measurements of NGAL.

For the first time, the article equips the clinical staff at the cardiac intensive care unit with a decision algorithm for the practical application of NGAL. BioPorto expects that the article will be given weight in the decision-making processes that lead to the inclusion of NGAL tests in official clinical guidelines, which in several countries are determined at a national level.

Peter Mørch Eriksen, CEO of BioPorto, said: "The Journal of Thoracic and Cardiovascular Surgery publishing the Advisory Board’s white paper is an important recognition of NGAL and a strategic milestone for BioPorto. I am convinced that the article with the suggested guidelines will open doors for NGAL-based tests worldwide and contribute to faster and improved renal injury diagnostics for the benefit of patients and clinicians."

About BioPorto Diagnostics A/S

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ OMX: BIOPOR Copenhagen stock exchange.
 
For questions or comments, please contact CEO Peter M. Eriksen.
Tel.: +45 4529 0000
info@bioporto.com